盐胁迫对喜钙念珠藻生理活性的影响及钙的胁迫缓解效应[J]

运用叶绿素荧光技术,结合光合放氧速率、pH等生理活性指标测定,研究了喜钙念珠藻(Nostoc calcicola Breb.)对盐的耐受能力及钙(Ca2+)对其所受胁迫的缓解作用.结果显示,喜钙念珠藻在盐度为12‰的环境中生长状态良好,与之相比在24‰盐度的处理组中生理活性则显著下降,其光合系统Ⅱ(PSⅡ)的活性和从活性反应中心到初级电子受体阶段的电子传递能力均受到了一定的抑制,但仍然持续生长,说明喜钙念珠藻对盐胁迫有较强的耐受性.1mmol/L的Ca2+就能够使光合放氧速率、叶绿素荧光值及光能吸收性能显著恢复.研究结果表明,Ca2+对光合系统和PSⅡ各活性反应中心有着重要的保护作用,并能够提..

孑遗植物四合木(Tetraena mongolica)迁地保护中的光合作用日变化特征与生理生态适应性

为了进一步廓清迁地保护条件下孑遗植物四合木(Tetraena mongolica)的光合生理生态适应性,在分析了瞬时光合效率的基础上,应用LI-6400光合作用测定系统测定了迁地保护试验区的四合木以及原生境伴生种白刺(Nitraria tangutorum)的光合作用日变化,并测定了其生长量。结果表明:四合木实生苗的生长南北冠幅大小依次为乌海四合木核心区实生苗(26.48cm×27.26 cm)>鄂尔多斯实生苗(21.27 cm×21.75 cm)>阿拉善实生苗(19.25 cm×18.27 cm)。在原生境地乌海四合木核心区种植的实生苗与阿拉善实生苗之间的生长量存在显著差异(P≤0.01),与鄂尔多斯实生苗之间的生长量存在显著差异(P≤0.05)。迁地保护条件下四合木生实生苗植株叶片光合速率Pn日变化均呈"双峰"曲线。不同试验区四合木光合作用日变化(Pn)、蒸腾速率(Tr)、气孔导度(Gs)和胞间CO2浓度(Ci)均表现出明显的分异。迁地保护四合木条件下原生境地栽培的四合木实生苗的光合速率>鄂尔多斯栽培的四合木实生苗的光合速率>阿拉善栽培的四合木实生苗。鉴此可以作进一步推论,孑遗濒危植物四合木从原生境地西鄂尔多斯核心区(乌海)东移进行迁地保护具有更高的生理生态适应性和生境适宜性。但完成"从种子到种子"进而实现"保存性和代表性",最终实现四合木迁地保护的"保持性和防止性",保持其遗传多样性和遗传稳定性,最终成功实现四合木的迁地保护仍有待作进一步探索和深入研究

新疆准噶尔北缘玉勒肯哈腊苏铜(钼)矿床流体包裹体和稳定同位素研究/Fluid inclusion and stable isotope study of Yulekenhalasu copper-(molybdenum) deposit in northern margin of Junggar, Xinjiang[J]

玉勒肯哈腊苏中型斑岩型铜(钼)矿主要赋存在闪长玢岩中,有少量矿化产在北塔山组火山岩及似斑状黑云母石英二长岩中.矿化呈细脉状、细脉-浸染状和浸染状.围岩蚀变主要为钾化、硅化、绢云母化、石膏化、磁铁矿化、绿泥石化、绿帘石化.矿床的形成经历了斑岩期、剪切变形期和表生期,铜和钼矿化主要形成于斑岩期的硫化物-钾硅酸盐阶段和辉钼矿阶段.石英和方解石中的流体包裹体可划分为H2 O-NaCl型和H2O-CO2(±CH4 /N2)-NaCl型.硫化物-钾硅酸盐阶段的成矿温度为141～500℃,主要集中在200～340℃;流体的ω(NaCleq)为2.96％～14.97％;流体的密度为0.60～ 0.98 g/cm3.碳酸盐阶段的流体以中-低温度(140～320℃)和低盐度[ω(NaCleq)为2.74％～10.61％]为特征.硫化物的δ34S值集中于-4.5‰～0.1‰,峰值为-3.5‰,表明硫来自深源岩浆.石英和方解石的δ18OSMOW值为9.1‰～13.2‰oo,δ18OH2O值为2.05‰～6.28‰,δD值为-120‰～ 97‰,表明主成矿阶段的成矿流体主要是岩浆水,混合有大气降水;碳酸盐阶段的流体主要为大气降水,混合有岩浆水.成矿时代为中泥盆世[(373.9±2.2 Ma)],成矿作用与闪长玢岩的侵入有关.温度和压力的降低导致流体沸腾,同时,水-岩交换反应、流体成分的改变等在铜钼成矿过程中起着主导作用

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies